Skip to main content

Advertisement

Log in

Alzheimer's disease

A firm base for drug development

  • News & Views
  • Published:

From Nature

View current issue Submit your manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Figure 1: Proposed mechanism by which the amyloid β (Aβ) peptide is generated through cleavage by the newly identified β-site APP-cleaving enzyme, BACE2,3,4,5.

References

  1. Haass, C. & Selkoe, D. J. Cell 75, 1039–1042 (1993).

    Article  CAS  Google Scholar 

  2. Vassar, R. et al. Science 286, 735–741 (1999).

    Article  CAS  Google Scholar 

  3. Hussain, I. et al. Mol. Cell. Neurosci. www.academicpress.com/www/journal/cn/mcne

  4. Yan, R. et al. Nature 402, 533–537 (1999).

    Article  ADS  CAS  Google Scholar 

  5. Sinha, S. et al. Nature 402, 537–540 (1999).

    Article  ADS  CAS  Google Scholar 

  6. Price, D. L. et al. Annu. Rev. Genet. 32, 461–493 (1998).

    Article  CAS  Google Scholar 

  7. Drews, J. Nature Biotechnol. 14, 1516–1518 (1996).

    Article  CAS  Google Scholar 

  8. Ren, S. & Lien, E. J. Prog. Drug Res. 51, 3–31 (1998).

    Google Scholar 

  9. Lichtenthaler, S. F. et al. Proc. Natl Acad. Sci. USA 96, 3053–3058 (1999).

    Article  ADS  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding authors

Correspondence to Bart De Strooper or Gerhard König.

Rights and permissions

Reprints and permissions

About this article

Cite this article

De Strooper, B., König, G. A firm base for drug development. Nature 402, 471–472 (1999). https://doi.org/10.1038/44973

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/44973

  • Springer Nature Limited

This article is cited by

Navigation